TITLE

Pipeline

PUB. DATE
January 2011
SOURCE
Pharmaceutical Representative;Jan2011, Vol. 41 Issue 1, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on the development of clinical trials for pharmaceutical drugs. It discusses the announcement of the positive results for the Phase III clinical study of the drug Corlux used for treatment of Cushing's Syndrome manufactured Corcept Therapeutics Inc. Also mentioned are the Phase II clinical trial results of the drugs PT003 by Pearl Therapeutics, Azixa for the treatment of glioblastoma multiforme by Myrexis, and Multimeric-001 flu vaccine by BiondVax Pharmaceuticals Ltd.
ACCESSION #
57458359

 

Related Articles

  • Corcept Raising $18M to Finish Corlux Testing.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p4 

    The article reports that Corcept Therapeutics Inc. plans to raise 18 million dollars to complete the Phase III study of Corlux (mifepristone) for the hormonal disorder Cushing's syndrome. The company will raise the fund through sale of stock and warrants that will be use to complete the study...

  • Much-Awaited Cushing's Data Positive, Corcept Plans Q1 NDA. Boggs, Jennifer // BioWorld Today;12/23/2010, Vol. 21 Issue 247, p1 

    The article reports on the announcement by Corcept Therapeutics Inc. of a positive top-line data from its Phase III trial of Corlux, a cortisol receptor antagonist for Cushing's syndrome. The news came as the biotechnology company is heading into ex-U.S. partnering talks. Despite the positive...

  • Corcept Raising $18M to Push Corlux Through Final Testing. Hollingsworth, Catherine // BioWorld Today;10/14/2009, Vol. 20 Issue 198, p3 

    The article reports on the move by Corcept Therapeutics Inc. to generate about 18 million U.S. dollars via the sale of stock and warrants. The money will be used to complete a Phase III study of the drug Corlux for Cushing's syndrome and to file for regulatory approval in 2010. Corlux is...

  • Clinic Roundup.  // BioWorld Today;10/12/2010, Vol. 21 Issue 197, p7 

    This section offers news briefs on clinical trials. A Phase III program was initiated by Auxilium Pharmaceuticals Inc. for Xiaflex in Peyronie's disease, or curvature of the penis. BiondVax Pharmaceuticals Ltd.'s Phase IIa trial of its universal influenza vaccine candidate, Multimeric-001, has...

  • Korlym: Orphan Drug OK'd.  // Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-20 

    The article offers information on the approval of the drug Korlym from Corcept Therapeutics Inc. by the U.S. Food and Drug Administration which will be used for the treatment of endogenous Cushing's syndrome.

  • Vaccine Report. Haniff, Haydia // BioPharm International;Feb2010, Vol. 23 Issue 2, p12 

    The article reports on the completion of the Phase 1-2 clinical trials of BiondVax Pharmaceuticals Ltd.'s influenza vaccine drug, Multimeric-001.

  • Other News To Note.  // BioWorld International;11/14/2012, Vol. 17 Issue 46, p6 

    This section offers news briefs on the pharmaceutical industry as of November 14, 2012. The U.S. Food and Drug Administration (FDA) granted an orphan drug designation to A4250, an inhibitor of the ileal bile acid transporter from Albireo AB of Gothenburg, Sweden. Aspireo Pharmaceuticals Ltd. of...

  • Novavax Offering Raises $82M for Flu Pandemic, RSV Efforts. Osborne, Randy // BioWorld Today;9/25/2013, Vol. 24 Issue 184, p1 

    The article reports that U.S. biopharmaceutical company Novavax Inc. is preparing for the next round of trials for its influenza vaccines. Novavax is set to close a public offering of shares to raise about 87 million dollars. The company's quadrivalent seasonal and pandemic flu vaccines are...

  • ITS' Flunisyn Elicits Strong T-Cell Response in Phase IIa. Moran, Nuala // BioWorld Today;4/17/2013, Vol. 24 Issue 73, p2 

    The article reports that England-based Immune Targeting Systems Ltd. (ITS) has presented positive data on its universal influenza vaccine, Flunisyn in a Phase IIa trial. Results show that Flunisyn induces strong T-Cell responses in 95% of subjects in an elderly population, ages 65 to 74. A Phase...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics